What is Servatus?
Founded in 2012 and headquartered in Coolum Beach, Queensland, Servatus operates at the intersection of biotechnology and immunology. The company is currently advancing a diverse portfolio of microbial-based drug candidates through rigorous human clinical trials. By targeting complex pathologies such as autoimmune, inflammatory, gastrointestinal, and dermatological conditions, Servatus is positioning itself as a disruptive force in the alternative medicine landscape. Its research-driven approach leverages advanced biological insights to address unmet medical needs, effectively bridging the gap between foundational science and patient-centric therapeutic solutions.
How much funding has Servatus raised?
Servatus has raised a total of $7.5M across 1 funding round:
Unspecified
$7.5M
Unspecified (2021): $7.5M, investors not publicly disclosed
Key Investors in Servatus
Undisclosed Investors
What's next for Servatus?
The infusion of capital is expected to catalyze the next phase of the company's lifecycle, specifically focusing on the expansion of clinical trial infrastructure and the optimization of manufacturing processes for its lead candidates. As Servatus moves deeper into the regulatory approval process, the strategic allocation of these funds will likely prioritize the scaling of its R&D capabilities and the strengthening of its intellectual property portfolio. Market observers anticipate that this financial backing will enable the firm to reach critical data inflection points, potentially setting the stage for future licensing agreements or strategic partnerships with global pharmaceutical entities looking to diversify their pipelines with innovative microbial therapies.
See full Servatus company page
